S2E91: Weltruza FDA Approval: What PMHNPs Need to Know
Podcast: Deep Dive with Lindsay Hill, DNP, PMHNP - Psych NP Mentor - PMHNP Mentor · Lindsay Hill
Opublikowano: 2026-11-03
Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode! Weltruza, the first monthly subcutaneous olanzapine LAI, drops the 3-hour observation. What PMHNPs need on dosing, PDSS, candidates, and metabolic monitoring. In this Deep Dive episode, two hosts walk through “Weltruza FDA Approval: What PMHNPs Need to Know” from the Psych NP Fellowship blog by Lindsay Hill, DNP, PMHNP-BC. Key takeaways: • On October 9, 2026, the FDA approved Weltruza, the first once-monthly subcutaneous olanzapine long-acting injectable (LAI), for adults with schizophrenia. • Three doses map to oral olanzapine: 318 mg = 10 mg/day, 425 mg = 15 mg/day...